ArticleFrontiers in cardiovascular medicine2024
The predictive role of the TAPSE/sPAP ratio for cardiovascular events and mortality in systemic sclerosis with pulmonary hypertension.
Article in Frontiers in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Association Between DLCO and Echocardiographic Right Ventricular-Pulmonary Arterial Coupling in Idiopathic Pulmonary Fibrosis.Journal of clinical medicine · 2026Article
- Long-Term Attrition in a 12-Month Adapted Physical Activity Program After Cardiac Rehabilitation: A Real-World Longitudinal Study.Journal of cardiovascular development and disease · 2026Article
- Mitochondrial Dysregulation and Molecular Signaling in Systemic Sclerosis Cardiac Disease: An Integrative Echocardiographic, Microvascular, and Biomarker Review.International journal of molecular sciences · 2026Review
- Correlation of Thoracic HRCT Scores with Right Heart Mechanics and TAPSE/sPAP Ratio in Pulmonary Alveolar Proteinosis.Journal of clinical medicine · 2026Article
- Interpreting Echocardiographic Right Ventricular-Pulmonary Arterial Coupling Indices After Transcatheter Tricuspid Intervention.Structural heart : the journal of the Heart Team · 2026Article
- Reproducibility of Echocardiographic Measurements of Right Ventricular Function: Comparison Between TAPSE and TDI S'.Journal of cardiovascular development and disease · 2026Article
- Diagnostic Performance of Quantitative Lung Perfusion SPECT/CT for Chronic Thromboembolic Pulmonary Hypertension: A Pilot Study.Diagnostics (Basel, Switzerland) · 2026Article
- Risk factors for different types of arrhythmias and their prognostic impact in patients with heart failure and concomitant pulmonary hypertension (PH-LHF): a large-scale retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Why Men Fare Worse: Understanding Gender Disparities in Systemic Sclerosis-Associated Pulmonary Hypertension.Clinical Medicine Insights. Cardiology · 2026Article
- Adherence to Exercise and Functional Rehabilitation Programs in Patients with Cardiovascular Diseases: Barriers and Strategies.Journal of cardiovascular development and disease · 2025Review
- Vitamin D insufficiency and cardiovascular involvement in systemic sclerosis: Association with echocardiographic parameters and risk factors.International journal of cardiology. Cardiovascular risk and prevention · 2025Article
- Prognostic Value of Body Weight-Independent Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Arterial Pressure Ratio in Canine Precapillary Pulmonary Hypertension: A Retrospective Study.Animals : an open access journal from MDPI · 2025Article
- Gender-Specific Differences in Diastolic Dysfunction and HFpEF: Pathophysiology, Diagnosis, and Therapeutic Strategies.Journal of cardiovascular development and disease · 2025Review
- The Diagnostic Value of Transthoracic Echocardiography Parameters Under the New Diagnostic Criteria for Pulmonary Hypertension.Canadian respiratory journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Reduced TAPSE/sPAP ratio has recently emerged as a predictive parameter risk factor for PH, however its role in SSc has been poorly investigated. The aim of the study was to investigate the prognostic value of the TAPSE/sPAP ratio for the prediction of mortality and cardiovascular events in patients with SSc complicated by PH. A comparison between SSc patients with PAH (SSc-PAH) and those with PH and significant ILD (SSc-PH) was also carried out. Materials and methods: A retrospective single-center study in which all patients having SSc-complicated by PH-referring to the Scleroderma-Unit of the AOU Policlinico of Modena, from October 2013 to October 2023 were evaluated. All SSc patients underwent recurrent clinical examination, routine blood chemistry analysis, functional, instrumental evaluation. Results: 61 SSc patients (F/M 52/9) were enrolled. During the follow-up, 60.1% of patients experienced at least one cardiovascular event and 62% died. The main causes of death were PH (39.4%) and other heart-related events (39.4%). The TAPSE/sPAP ratio was significantly lower in deceased patients compared to survivors (mm/mmHg 0.3 ± 0.12SD vs. 0.48 ± 0.17SD, Conclusion: Our work confirmed the predictive role of the TAPSE/sPAP ratio for mortality and cardiovascular events in patients with SSc complicated by PH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.